Aardvark Pauses Phase 3 Trials for ARD-101 Due to Cardiac Safety Concerns; Provides Q4/FY25 Financials
Summary
Aardvark Therapeutics has voluntarily paused its Phase 3 trials for ARD-101 and ARD-201 programs following unexpected reversible cardiac observations in a healthy volunteer study, while also reporting increased losses for Q4 and full year 2025.
Key Events
-
Phase 3 Trial Pause
Aardvark has voluntarily paused enrollment and dosing in its Phase 3 HERO and OLE trials for ARD-101 (Prader-Willi Syndrome) and its ARD-201 obesity program.
-
Cardiac Safety Concerns Identified
The pause follows unexpected reversible cardiac observations (QRS duration increases) in a separate healthy volunteer trial, with preliminary analysis indicating an exposure-response relationship at higher plasma concentrations.
-
Regulatory Engagement and Program Delay
The company is actively engaging with the FDA to determine next steps and expects to provide further guidance on its programs in the second quarter of 2026.
-
Increased Net Loss for 2025
Aardvark reported a net loss of $57.6 million for the full year ended December 31, 2025, compared to a net loss of $20.6 million for the prior year, driven by higher R&D and G&A expenses.
Analysis
The voluntary pause of Aardvark's lead Phase 3 program (ARD-101 for Prader-Willi Syndrome) and its ARD-201 obesity program represents a significant setback. While the company states the cardiac observations were reversible and not serious adverse events, and an exposure-response relationship has been identified, this introduces substantial uncertainty and delays for its key pipeline assets. The company is engaging with the FDA and expects to provide further guidance in Q2 2026, leaving investors in a holding pattern. This news comes as the company reports increased R&D and G&A expenses, leading to a larger net loss for 2025, though its cash position provides runway into Q2 2027. The market is likely to react negatively to the trial delays and safety questions, especially given the stock is already trading near its 52-week low.
At the time of this filing, AARD was trading at $4.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $88.5M. The 52-week trading range was $4.01 to $17.94. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.